Pyoderma gangrenosum is a rare neutrophilic, inflammatory disorder. A recent study from Finland has analysed patient records with post-surgical pyoderma gangrenosum with special focus on the diagnostic delay and treatment outcomes.

**ABSTRACT**

**Background**

Pyoderma gangrenosum (PG) is a rare neutrophilic disease that is characterised by the pathergy phenomenon, as it worsens with trauma. Post-surgical PG (PSPG) occurs in surgical incisions and is typically first misdiagnosed as a surgical site infection. The diagnostic delay in PSPG is often considerable.

**Hypothesis/Aim**

The aim of this study was to analyse patient records with PSPG that were diagnosed in our Department of Dermatology; with special focus on the diagnostic delay and treatment outcomes.

**Methods**

The records of four patient cases that were diagnosed with PSPG in our Department of Dermatology from 2017 to 2018 were analysed retrospectively.

**Results**

The average delay in diagnosis was 5 months, and the diagnosis could not rely on histological findings. Prednisolone treatment led to complete wound healing in three cases. In one case, switching from prednisolone to cyclosporine eventually healed the wound.

**Conclusions**

The diagnostic delay was considerable, and prednisolone and cyclosporine were considered as effective treatments.

**Implications for clinical practice**

This report emphasises the importance of early suspicion and recognition in PSPG cases, and early referral to dermatologist.

**INTRODUCTION**

Pyoderma gangrenosum (PG) is a rare neutrophilic, inflammatory disorder. The typical presentation involves a papulo-pustule with violaceous inflamed borders evolving into enlarging, painful, undermined wounds. However, the clinical picture can vary greatly. Therefore, diagnosing these wounds can be challenging for the clinician. Recently, two reports on the diagnostic criteria have been published. It is important to keep in mind that PG is usually a diagnosis of exclusion. Often, a positive response to immunosuppressive treatment ultimately confirms the diagnosis.

Several reports have also described post-surgical PG (PSPG). PSPG has been reported to occur most frequently after breast surgery, followed by cardiothoracic, abdominal, and obstetric surgeries. With PSPG, the association of typical PG comorbidities, such as inflammatory bowel disease (IBD), rheumatoid arthritis, and haematologic malignancies, may not be strong. The real challenge in PSPG for both the clinician and patient is the delay in diagnosis. Typically, it is first misdiagnosed as a surgical site infection (SSI), but the wounds continue to enlarge or remain unhealed despite revisions and antibiotic treatment.
(Table 1). Data from patient records were collected and included comorbidities, type of surgery, diagnostic delay (assessed from first symptoms to the diagnosis date), histological report, treatment, and time to complete wound healing after starting immunosuppressive therapy. This retrospective study protocol followed the ethical guidelines of the Declaration of Helsinki (2013). Photographs were included after permission from the patients was obtained.

RESULTS

Patient characteristics are shown in Table 1. One patient had IBD (colitis ulcerosa), and one patient had rheumatoid arthritis (Figures 1a and 1b). Histology was not specific in most of the cases. The diagnosis was mainly established by the following criteria: the clinical picture and wound history, lack of response to earlier treatments (e.g., revisions, antibiotics), and a positive response to immunosuppressive therapy. The average time from the onset of symptoms until diagnosis was 5 months. Initially, treatment relied on prednisolone in all patients. In one patient, prednisolone was switched to cyclosporine, after which the wound eventually healed (Figures 2a, b, c, and d). Local wound therapy was designed according to the TIME (T=tissue, I=infection/inflammation, M=moisture, E=edge) protocol.

DISCUSSION

PG was first described by a French dermatologist named Brocq in 1916. It is an uncommon neutrophilic disorder, which presents as inflamed pustules and ulcers similar to an infectious disease. This clinical picture and negative histology in many cases render the diagnosis challenging. However, holistic patient assessment is essential and aids the diagnosis in these patients. “It is not the hole in the patient but the whole patient” is a valid argument in PG patients. Different comorbidities, such as IBD, hematologic malignancies, and rheumatoid arthritis, can give clues for PG diagnosis. Because IBD is such a common comorbidity, any wounds of interest in a patient with IBD can be considered a PG wound, until otherwise proven. Importantly, PG lesions occur in up to 50% of cases and are most commonly located at sites of cutaneous trauma, such as venepuncture, laparoscopy, and surgical incisions; this phenomenon is known as pathergy. PSPG refers to the development of PG at surgical sites in the immediate post-operative period, typically 1 week after surgery. The literature has described SSI as a frequent misdiagnosis, and mortality has been reported. However, the ulcers do not respond to antibiotic therapy and continue to enlarge after revisions, due to the pathergy phenomenon. From the patient’s perspective, there is a substantial delay in diagnosis time and decreased health-related quality of life due to pain, continuous wound management, and unnecessary surgical treatments.

The aim of this study was to retrospectively analyse PSPG patients who were diagnosed and treated in our Dermatology Unit. The average delay in diagnosis was 5 months, which was the time from first symptoms to first dermatologic consultation. We believe this to be quite a long time, as PG ulcers usually heal very slowly after exact diagnosis and optimal treatment. The treatment relies on immunosuppressive therapy, and the first-line treatment option is high-dose prednisolone. After the suppression of inflammatory activity, a steroid-sparing agent is often combined to avoid the adverse reactions of high-dose steroids. However, in a randomised multicentre trial with 112 participants, cyclosporin and prednisolone did not differ across a range of objectives and patient-reported outcomes. Thus, it was concluded that the first-line drug should be decided based on each patient’s characteristics. In hard-to-heal PG wounds, biologic treatment is also an option. When the inflammatory reaction has been reduced by immunosuppressive therapy, negative-pressure...
Table 1. Analysis of four post-surgical pyoderma gangrenosum patient cases.

<table>
<thead>
<tr>
<th>PATIENT</th>
<th>OPERATION</th>
<th>DELAY IN DIAGNOSIS</th>
<th>HISTOLOGY</th>
<th>TREATMENT</th>
<th>TIME FOR COMPLETE WOUND HEALING</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male 59 years</td>
<td>Liberation of the ulnar nerve in the left arm</td>
<td>5 months</td>
<td>Granulation tissue and mixed inflammatory cell infiltrate with neutrophils</td>
<td>1. Prednisolone 20 mg/day + mycophenolate mofetil 2000 mg/day for 9 months</td>
<td>After starting cyclosporine, 5 months</td>
</tr>
<tr>
<td>Female 16 years</td>
<td>Rotation osteotomy due to femoral fracture</td>
<td>4 months</td>
<td>Granulation tissue with a lymphocytic infiltrate</td>
<td>Prednisolone 30 mg/day</td>
<td>2 months</td>
</tr>
<tr>
<td>Female 33 years</td>
<td>Mastectomy due to BRCA1-mutation</td>
<td>11 months</td>
<td>Biopsy not taken, clinical diagnosis</td>
<td>Prednisolone 40 mg/day</td>
<td>1 month</td>
</tr>
<tr>
<td>Female 31 years</td>
<td>Knee arthroplasty</td>
<td>1 month</td>
<td>Neutrophilic inflammation</td>
<td>Prednisolone 30 mg/day</td>
<td>2 months</td>
</tr>
</tbody>
</table>

In our patients, prednisolone treatment led to complete wound healing in three cases during a period of 1–2 months. This prompt response to immunosuppressive therapy ultimately confirmed the diagnosis of PSPG. In one case, prednisolone 20 mg/day for 9 months was ineffective, but cyclosporine eventually led to wound healing during a period of 5 months. The ineffectiveness of prednisolone in this case could potentially be influenced by the relatively low dose (20 mg/day) that was used, as the patient weighed 101 kg. Usually, the recommended dose of prednisolone ranges from 0.5–0.75 mg/kg/day. It is important to note that histology was not specific for PG in any of our cases. Typical histological findings were hypergranulation and mixed inflammatory infiltrate. Therefore, it is important that PG is not excluded by histological findings alone. In addition, the value of histology depends strongly on the site of biopsy. Optimally, surgeons and surgical nurses should be aware of this entity and recognise “danger” signs that highlight the need for dermatologic consultation. These signs include a previous history of PG, familial history of PG, IBD, haematologic malignancy, rheumatoid arthritis, negative wound swabs or unresponsiveness to antibiotic therapy, violaceous wound borders, and enlargement of wounds by revisions. Indeed, PG is a diagnosis that clinicians “wish you had never operated on.”

Finally, PG and PSPG are part of the family of atypical wounds, which deserve better recognition and treatment among health care professionals. The European Wound Management Association (EWMA) has established a working group to gather the best available knowledge on atypical wounds, and the EWMA Document on Atypical Wounds will be published in spring 2019. This document is targeted at increasing awareness of the clinical picture, diagnosis, and treatment of these wounds. It also aims to provide practical advice on some of the challenges that typically arise in the diagnosis or treatment of inflammatory and vasculopathy wounds, such as PG, malignant wounds, and cutaneous vasculitis.

CONCLUSIONS

PSPG is an important differential diagnosis for SSI. Prompt suspicion and recognition, as well as a dermatologic consultation, are necessary for favourable outcomes in these cases. The disease can also be fatal. Despite a considerable delay in diagnosis, our study showed favourable outcomes after exact diagnosis and immunosuppressive treatment.
REFERENCES

Figures 2a,b,c and d. Post-surgical pyoderma gangrenosum in the surgical scar of an ulnar nerve liberation. Figure 2a shows the wound before treatment. Figure 2b shows 9 months after prednisolone treatment. Figure 2c shows 1 month after the starting of cyclosporine. Figure 2d shows complete wound healing after 5 months of cyclosporine treatment.